In Re Rezulin Products Liability Litigation
Defendants Pfizer, Inc. sought summary judgment against nine plaintiffs in an MDL concerning the diabetes drug Rezulin. The plaintiffs claimed either no injury, fear of future injury, or subcellular mitochondrial damage. The court ruled that while subcellular injury might establish Article III standing, it was not a compensable injury under Texas law without a clinically manifest detriment. Similarly, claims for fear of future injury failed under both Texas and Louisiana law due to the absence of a manifest physical injury or special circumstances. Economic claims for fraud and redhibition under Louisiana law were also dismissed. Consequently, the court granted Pfizer's motion for summary judgment, dismissing the claims of the specified plaintiffs.